Considering that cognitive impairment in AD is more strongly associated with tau pathology than with Aβ deposition, further research is needed to elucidate APOA-I’s direct influence on tau pathogenesis and its potential to block Aβ-induced tauopathy in AD models. This evidence concerns the gene MAPT and tauopathy.